Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

The study systematically characterized RILD using bronchoalveolar lavage and high-resolution CT in 321 patients, mostly with ...

The usually slow-growing follicular lymphoma The often more aggressive diffuse large B-cell lymphoma For decades, treatments for non-Hodgkin's lymphoma remained stuck in neutral. Conventional ...

"With almost all provinces onboard, urgent medicines can now be more accessible to patients with diseases such as R/R DLBCL across the country," said Antonella Rizza, CEO, Lymphoma Canada.

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...

Imugene Limited (AU:IMU) has released an update. Imugene Limited has reported promising progress in its clinical trials, including three ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Detailed price information for Adaptive Biotechnologies Corp (ADPT-Q) from The Globe and Mail including charting and trades.

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes #469 oral presentation Session: 626.